Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Misses Estimates By $0.04 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) issued its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), FiscalAI reports. Day One Biopharmaceuticals had a negative return on equity of 23.14% and a negative net margin of 67.85%.The business had revenue of $53.72 million for the quarter, compared to analysts’ expectations of $49.81 million.

Here are the key takeaways from Day One Biopharmaceuticals’ conference call:

• OJEMDA commercial traction: 2025 net product revenue was $155.4M (up 172% YoY) with Q4 revenue of $52.8M and >4,600 prescriptions; management reiterated 2026 OJEMDA guidance of $225M–$250M.
• Three‑year FIREFLY‑1 data strengthen clinical case: company reports a 53% objective response rate, median response duration ~19.4 months, no new safety signals, and a median time‑to‑next‑treatment (TTNT) of 42.6 months versus a 16.6‑month PFS, which management says supports durable clinical benefit.
• Pipeline and BD progress: acquisition of Mersana closed in January to add Emi‑Le (early activity in adenoid cystic carcinoma) with an updated dataset planned for mid‑2026 and potential accelerated development, plus DAY301 early signals expected H2 2026.
• Concentration and timing risks remain: Day One is heavily dependent on OJEMDA as its primary revenue driver and future performance hinges on persistence, new patient starts, payer dynamics, and successful enrollment/readout of FIREFLY‑2 (top‑line mid‑2027); statements are forward‑looking and company‑presented.

Day One Biopharmaceuticals Trading Down 3.4%

Shares of NASDAQ DAWN traded down $0.37 on Thursday, reaching $10.56. 449,269 shares of the company traded hands, compared to its average volume of 2,437,323. Day One Biopharmaceuticals has a fifty-two week low of $5.64 and a fifty-two week high of $13.20. The company has a 50 day moving average of $10.67 and a 200 day moving average of $8.76. The stock has a market capitalization of $1.08 billion, a PE ratio of -10.34 and a beta of -1.26.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 6,065 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer owned 312,025 shares of the company’s stock, valued at $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Adam Dubow sold 6,395 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the completion of the transaction, the insider owned 72,694 shares in the company, valued at approximately $843,250.40. This trade represents a 8.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 36,461 shares of company stock valued at $422,948. 6.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in DAWN. Rubric Capital Management LP acquired a new position in Day One Biopharmaceuticals in the third quarter valued at $23,808,000. Vestal Point Capital LP raised its holdings in shares of Day One Biopharmaceuticals by 94.4% in the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock worth $48,464,000 after purchasing an additional 2,525,000 shares during the period. Balyasny Asset Management L.P. purchased a new position in shares of Day One Biopharmaceuticals in the 3rd quarter worth about $9,758,000. Millennium Management LLC lifted its stake in shares of Day One Biopharmaceuticals by 587.2% in the 1st quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock valued at $10,468,000 after purchasing an additional 1,127,995 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Day One Biopharmaceuticals by 232.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock worth $12,449,000 after purchasing an additional 1,097,679 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. HC Wainwright dropped their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 26th. Wedbush lifted their price target on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Needham & Company LLC cut their price objective on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.14.

Trending Headlines about Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Company beat revenue expectations and reiterated 2026 guidance — Q4 net product revenue was $52.8M and FY2025 net product revenue was $155.4M; management reaffirmed 2026 U.S. net product revenue guidance of $225M–$250M and highlighted the January acquisition of Mersana (adds Emi‑Le into Phase 1 for ACC), supporting growth outlook. Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
• Positive Sentiment: Wedbush raised its price target to $30 and kept an “outperform” rating — a bullish signal that suggests optimistic upside versus the current price and may attract buyers. TickerReport: Wedbush raises PT
• Neutral Sentiment: Full earnings materials and call transcripts are available (slide deck, conference call transcript) for deeper due diligence — useful for investors assessing margin trajectory, commercialization cadence, and pipeline integration. Q4 2025 Results — Slide Deck / Press Release
• Neutral Sentiment: Analyst commentary roundup is circulating summarizing the mixed reception to the print — helpful context but not a direct catalyst. What Analysts Are Saying About Day One Biopharmaceutical Stock
• Neutral Sentiment: Reported short interest data for February appears effectively zero/erroneous (dataset shows 0 shares / NaN increase), so short pressure does not explain today’s move. (Data looks unreliable.)
• Negative Sentiment: EPS missed consensus — reported GAAP EPS of ($0.21) vs. estimate of ($0.17), and the company still shows negative margins and ROE; that earnings miss is a near-term headwind for sentiment. DAWN Q4 Results / Transcript
• Negative Sentiment: Two firms trimmed price targets — Needham cut its PT to $17 (still a “buy”) and HC Wainwright lowered its PT to $22 — these downgrades to upside expectations can weigh on near-term investor enthusiasm despite buy ratings. Benzinga: Analyst PT changes

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.